维立西呱治疗慢性心力衰竭的效果分析

Effect Analysis of Vericiguat in Treatment of Chronic Heart Failure

目的:探讨维立西呱治疗慢性心力衰竭(CHF)的效果。方法:选取2022年11月—2023年10月徐州医科大学第二附属医院/徐州矿务集团总医院心内科收治的92例CHF患者作为研究对象,以随机数字表法分为常规组与治疗组,各46例。常规组接受常规疗法,治疗组在常规组基础上采用维立西呱治疗。比较两组治疗效果。结果:治疗后,两组左室舒张末期内径、左室收缩末期内径低于治疗前,且治疗组低于常规组,两组左室射血分数高于治疗前,且治疗组高于常规组,差异均有统计学意义(P<0.05)。治疗后,两组血清N末端脑钠肽前体、肌酸激酶同工酶水平低于治疗前,且治疗组低于常规组,差异均有统计学意义(P<0.05)。治疗后,两组血清C反应蛋白、白细胞介素-6、脂蛋白相关磷脂酶A2水平均低于治疗前,且治疗组低于常规组,差异均有统计学意义(P<0.05)。结论:维立西呱治疗CHF的效果较好,可抑制心室重构,下调心脏生化标志物表达水平,减轻机体炎性反应。

Objective:To explore the effects of vericiguat in treatment on chronic heart failure(CHF).Methods:From November 2022 to October 2023,92 CHF patients admitted to Department of Cardiology at the Second Affiliated Hospital of Xuzhou Medical University/Xuzhou Coal Mining Group General Hospital were selected as the study subjects.According to the random digital table method,they were divided into conventional group and treatment group,with 46 cases in each group.The conventional group re-ceived conventional treatment.The treatment group received vericiguat treatment on the basis of conventional group.The treat-ment effects of the two groups were compared.Results:After treatment,the left ventricular end-diastolic diameter and left ven-tricular end-systolic diameter in two groups were lower than those before treatment,and these indicators in the treatment group were lower than those in the conventional group,while the left ventricular ejection fraction in the two groups was higher than that before treatment,and this indicator in the treatment group was higher than that in the conventional group,and the difference was statistically significant(P<0.05).After treatment,the levels of serum N-terminal brain natriuretic peptide precursor and creatine kinase isoenzyme in the two groups were lower than those before treatment,the levels in the treatment group were lower than those in the conventional group,and the difference was statistically significant(P<0.05).After treatment,the levels of serum C-reactive protein,interleukin-6 and lipoprotein-associated phospholipase A2 in the two groups were lower than those before treatment,the levels in the treatment group were lower than those in the conventional group,and the difference was statistically significant(P<0.05).Conclusion:Vericiguat has good effects in treatment of CHF,and can suppress the ventricular remodeling,down-regulate the expression level of heart biomarkers,and reduce the inflammatory reaction of the body.